AbbVie vs Bristol Myers Squibb
탄탄한 현금흐름을 보유한 기존 바이오제약 기업 vs 종양학 및 면역학 의약품을 보유한 다각화 바이오제약 기업. 9월 2026에 내 포트폴리오에 더 잘 맞는 종목은 무엇일까요? 아래에서 쉽게 설명합니다.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer drug franchise anchored by Opdivo and Eliquis. Both pharma giants are navigating the same brutal patent cliff cycle and deploying billions in M&A to replenish revenue. AbbVie vs Bristol Myers Squibb puts two of the industry's biggest cash-flow machines side by side to compare their pipeline depth, dividend sustainability, and long-term growth bets.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer dr...
주가 변동 요인
AbbVie gets a pipeline boost as recent trial wins and a deal closing sharpen the growth story.
- Positive late-stage cancer data gave investors a fresh growth signal, with AbbVie saying its etentamig trial met both primary goals and meaningfully cut the risk of disease progression or death.
- A new positive Phase 3 readout for atogepant in menstrual migraine added to the sense that AbbVie’s pipeline is producing multiple near-term catalysts beyond its core immunology franchise.
- AbbVie also completed its Apogee acquisition, reinforcing its push to diversify growth while the company reaffirmed 2026 earnings guidance, which helped steady sentiment around execution and cash-generation.
BMY jumps on promising CAR-T data, but analysts still see downside risk as pipeline uncertainty lingers.
- Positive Phase 2 CAR-T data for arlocabtagene autoleucel gave the stock a lift, but the move also looked driven by investors rotating around a still-early pipeline story rather than a full rerating.
- Recent attention around pauses in autoimmune CAR-T programs has kept risk perceptions elevated, underscoring how quickly trial safety headlines can offset encouraging clinical updates.
- Analyst commentary pointing to downside risk has likely reflected that tension: a steady core pharma franchise is helping support the shares, while pipeline execution remains the key swing factor.
AbbVie gets a pipeline boost as recent trial wins and a deal closing sharpen the growth story.
- Positive late-stage cancer data gave investors a fresh growth signal, with AbbVie saying its etentamig trial met both primary goals and meaningfully cut the risk of disease progression or death.
- A new positive Phase 3 readout for atogepant in menstrual migraine added to the sense that AbbVie’s pipeline is producing multiple near-term catalysts beyond its core immunology franchise.
- AbbVie also completed its Apogee acquisition, reinforcing its push to diversify growth while the company reaffirmed 2026 earnings guidance, which helped steady sentiment around execution and cash-generation.
BMY jumps on promising CAR-T data, but analysts still see downside risk as pipeline uncertainty lingers.
- Positive Phase 2 CAR-T data for arlocabtagene autoleucel gave the stock a lift, but the move also looked driven by investors rotating around a still-early pipeline story rather than a full rerating.
- Recent attention around pauses in autoimmune CAR-T programs has kept risk perceptions elevated, underscoring how quickly trial safety headlines can offset encouraging clinical updates.
- Analyst commentary pointing to downside risk has likely reflected that tension: a steady core pharma franchise is helping support the shares, while pipeline execution remains the key swing factor.
투자 분석
AbbVie
ABBV
장점
- AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
- Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
- Humira successors demonstrate high-teens growth potential offsetting legacy product declines.
고려 사항
- Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
- Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
- High debt levels from past acquisitions elevate financial risk in rising interest environment.
장점
- Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
- Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
- Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.
고려 사항
- Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
- Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
- Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.
AbbVie(ABBV) 다음 실적 발표일
AbbVie’s next earnings report is typically expected around October 30, 2026, based on its historical reporting pattern and current market estimates. That release should cover Q3 2026 results. For an exact announcement date, the company has not yet formally confirmed the schedule.
Bristol Myers Squibb(BMY) 다음 실적 발표일
Bristol Myers Squibb’s next earnings date is expected to be October 29, 2026. The report should cover Q3 2026 results. This timing is consistent with the company’s recent quarterly reporting pattern and market estimates.
AbbVie(ABBV) 다음 실적 발표일
AbbVie’s next earnings report is typically expected around October 30, 2026, based on its historical reporting pattern and current market estimates. That release should cover Q3 2026 results. For an exact announcement date, the company has not yet formally confirmed the schedule.
Bristol Myers Squibb(BMY) 다음 실적 발표일
Bristol Myers Squibb’s next earnings date is expected to be October 29, 2026. The report should cover Q3 2026 results. This timing is consistent with the company’s recent quarterly reporting pattern and market estimates.
Nemo에서 ABBV 또는 BMY 매수하기
수수료 무료
주식, ETF 등을 수수료 없이 거래하세요. 수익을 더 많이 지키세요.
신뢰할 수 있는 규제 기관 인가
2015년부터 Exinity Group의 일원으로, 전 세계 100만 명 이상의 고객에게 서비스를 제공합니다.
현금 예치금 6% 이자
투자하지 않은 현금에 연 6%(AER) 이자를 매일 지급합니다.
